Circulating interferon-α2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation

Lupus

Volumn 22, Issue 2, 2013, Pages 155-163

  Becker Merok, A ^a   Ostli Eilersten G ^a   Lester, S ^b   Nossent, J C ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

cytokines; Interferon; Systemic Lupus Erythematosus

Indexed keywords

ALPHA2 INTERFERON; AUTOANTIBODY; B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; PREDNISONE; RIBOSOMAL PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE COMPARISON; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 84872579202     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312468964     Document Type: Article

References (48)

1. Finke D, Eloranta ML, Ronnblom L. Endogenous type I interferon inducers in autoimmune diseases. Autoimmunity. 2009 ; 42: 349-352
2. Crow MK. Type I interferon and autoimmune disease. Autoimmunity. 2003 ; 36: 445-446
3. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 ; 301: 5-8 (Pubitemid 9226519)
4. Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun. 2001 ; 17: 71-80 (Pubitemid 32751883)
5. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004 ; 50: 1861-1872 (Pubitemid 38725099)
6. Kirou KA, Lee C, Crow MK. Measurement of cytokines in autoimmune disease. Methods Mol Med. 2004 ; 102: 129-154
7. Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol. 2004 ; 16: 541-547
8. Cantaert T, De Rycke L, Mavragani CP, et al. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009 ; 68: 1022-1029
9. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: A time for new paradigms?. Arthritis Rheum. 2003 ; 48: 300-312 (Pubitemid 36277996)
10. Riboldi P, Gerosa M, Moroni G, et al. Anti-DNA antibodies: A diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity. 2005 ; 38: 39-45 (Pubitemid 40515002)
11. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557 (Pubitemid 44205016)
12. Gordon C, Bertsias G, Ioannidis JP, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2009 ; 68: 470-476
13. Eloranta ML, Barbasso HS, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007 ; 56: 3112-3124 (Pubitemid 47502759)
14. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011 ; 23: 113-121
15. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006 ; 54: 1917-1927 (Pubitemid 43877941)
16. Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol. 2006 ; 33: 1785-1788 (Pubitemid 44373212)
17. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: The role of analytical diversity. Ann Rheum Dis. 2004 ; 63: 386-394 (Pubitemid 38453304)
18. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008 ; 358: 929-939 (Pubitemid 351397092)
19. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 1044-1053
20. Eilertsen GO, Becker-Merok A, Nossent JC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: Epidemiology, disease presentation, and patient management. J Rheumatol. 2009 ; 36: 552-559
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
22. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 ; 29: 288-291 (Pubitemid 34118775)
23. Gladman D, Ginzler E, Goldsmith C, et al. Systemic lupus international collaborative clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol. 1992 ; 19: 1820-1821
24. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006 ; 15: 570-576 (Pubitemid 44661743)
25. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol. 2007 ; 316: 359-386
26. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 ; 301: 5-8 (Pubitemid 9226519)
27. Suit BE, Axelrod D, Moutsopoulos HM, Decker JL, Hooks JJ. Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol. 1983 ; 1: 133-135 (Pubitemid 13011400)
28. Kirou KA, Kalliolias GD. A new tool for detection of type I interferon activation in systemic lupus erythematosus. Arthritis Res Ther. 2010 ; 12: 138-138
29. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011 ; 70: 2029-2036
30. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000 ; 9: 664-671 (Pubitemid 32011791)
31. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum. 2009 ; 60: 3098-3107
32. Karageorgas TP, Tseronis DD, Mavragani CP. Activation of type I interferon pathway in systemic lupus erythematosus: Association with distinct clinical phenotypes. J Biomed Biotechnol. 2011 ; 2011: 273 907-273 907
33. Liao AP, Salajegheh M, Morehouse C, et al. Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin Immunol. 2010 ; 136: 130-138
34. Hillyer P, Mane VP, Schramm LM, et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol. 2012 ; 90: 774-783
35. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008 ; 58: 2113-2119 (Pubitemid 351988103)
36. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005 ; 52: 1491-1503 (Pubitemid 40663941)
37. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009 ; 18: 980-989
38. Kirou KA, Mavragani CP, Crow MK. Activation of type I interferon in systemic lupus erythematosus. Expert Rev Clin Immunol. 2007 ; 3: 579-588 (Pubitemid 47091233)
39. Ritterhouse LL, Crowe SR, Niewold TB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011 ; 63: 3931-3941
40. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 2009: pii: 374312.
41. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol. 2008 ; 67: 185-192
42. Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol. 2008 ; 38: 1058-1064
43. Weckerle CE, Mangale D, Franek BS, et al. Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64: 2947-2952
44. Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 1993 ; 2: 359-365
45. Miret C, Font J, Molina R, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 2001 ; 21: 3053-3059 (Pubitemid 33051175)
46. Rahman A. Cytokines in systemic lupus erythematosus, London, UK. Arthritis Res Ther. 2003 ; 5: 160-164 (Pubitemid 36926681)
47. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009 ; 60: 1785-1796
48. Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011 ; 56: 282-289